Live Stock Coverage: Today Opko Health Inc. Stock Crashes

Live Stock Coverage: Today Opko Health Inc. Stock Crashes

The stock of Opko Health Inc. (NASDAQ:OPK) is a huge mover today! About 4.92M shares traded hands or 60.78% up from the average. Opko Health Inc. (NASDAQ:OPK) has declined 8.90% since April 6, 2016 and is downtrending. It has underperformed by 10.85% the S&P500.
The move comes after 9 months negative chart setup for the $4.95 billion company. It was reported on Nov, 8 by We have $8.60 PT which if reached, will make NASDAQ:OPK worth $247.50M less.

Analysts await Opko Health Inc. (NASDAQ:OPK) to report earnings on November, 14. They expect $-0.03 EPS, down 112.00% or $0.28 from last year’s $0.25 per share. After $0.02 actual EPS reported by Opko Health Inc. for the previous quarter, Wall Street now forecasts -250.00% negative EPS growth.

According to Zacks Investment Research, “OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies.”

Insitutional Activity: The institutional sentiment increased to 1 in Q2 2016. Its up 0.16, from 0.84 in 2016Q1. The ratio increased, as 33 funds sold all Opko Health Inc. shares owned while 63 reduced positions. 22 funds bought stakes while 74 increased positions. They now own 102.34 million shares or 2.14% more from 100.19 million shares in 2016Q1.
Rhumbline Advisers reported 313,120 shares or 0.01% of all its holdings. Citadel Advisors Limited Co, a Illinois-based fund reported 324,644 shares. Commerzbank Aktiengesellschaft Fi holds 0% of its portfolio in Opko Health Inc. (NASDAQ:OPK) for 28,190 shares. Us Financial Bank De has invested 0% of its portfolio in Opko Health Inc. (NASDAQ:OPK). Fmr Llc has 0% invested in the company for 2.08 million shares. Morgan Stanley holds 0.02% or 4.92 million shares in its portfolio. The United Kingdom-based Legal General Group Inc Public Ltd Co has invested 0% in Opko Health Inc. (NASDAQ:OPK). Envestnet Asset Management Incorporated, a Illinois-based fund reported 11,356 shares. Manufacturers Life Insurance Com The, a Ontario – Canada-based fund reported 15,603 shares. Price T Rowe Assoc Md holds 0% or 919,171 shares in its portfolio. Cubist Systematic Strategies Ltd Company owns 20,521 shares or 0.01% of their US portfolio. Exchange Cap Mngmt holds 0% of its portfolio in Opko Health Inc. (NASDAQ:OPK) for 30 shares. Highlander Management Limited Liability Co last reported 54,723 shares in the company. Stevens Mngmt L P reported 372,052 shares or 0.14% of all its holdings. Proshare Limited Liability Company has 0% invested in the company for 10,655 shares.

Insider Transactions: Since May 11, 2016, the stock had 59 buys, and 0 insider sales for $5.44 million net activity. On Thursday, June 9 the insider FROST PHILLIP MD ET AL bought $48,677.

OPK Company Profile

OPKO Health, Inc. (OPKO), incorporated on November 18, 1991, is a healthcare company. The Firm operates through two divisions: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical activities in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations. The Company’s diagnostics business includes Bio-Reference Laboratories (Bio-Reference), which is a clinical laboratory with a genetic testing business, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The Company’s pharmaceutical business features Rayaldee, a treatment for secondary hyperparathyroidism (SHPT) in patients with stage III or IV chronic kidney disease (CKD) and vitamin D insufficiency and VARUBI for chemotherapy-induced nausea and vomiting. The Company’s pharmaceutical business includes OPKO Biologics, which features hGH-CTP, a once-weekly human growth hormone injection (in Phase III and partnered with Pfizer), and a longer acting Factor VIIa drug for hemophilia (Phase IIa). In addition to its pharmaceutical and diagnostic development programs, it owns pharmaceutical platforms in Ireland, Chile, Spain and Mexico. The Firm has a development and commercial supply pharmaceutical company, as well as a global supply chain operation and holding firm in Ireland. It also owns a specialty active pharmaceutical ingredients (APIs) maker in Israel.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment